LamdaGen Receives Japanese Patent for Enzymatic Diagnostic Assays on Plasmonic Nanosensors

Published on April 5, 2013 at 5:09 AM

LamdaGen Corporation, a nano-technology platform company that provides plasmonic sensors and systems for diagnostics and life sciences, announced the Japanese Patent Office issuance of patent number 5203390, "Enzymatic Assays for LSPR", which enables highly sensitive and quantitative diagnostics.

"The issuance of this patent underscores LamdaGen's unique ability to harness the significant potential of modern plasmonics in greatly enhancing the detection sensitivity and speed of current immuno-diagnostics," commented Randy Storer , CEO and Co-Founder of LamdaGen Corporation. "We are working with a number of companies to integrate our powerful technology into their existing diagnostic systems and devices or advanced IVD systems they have under development."

The patent claims broadly cover nano-plasmonic surfaces and particles used in various ways as solid supports for high-speed plasmonic ELISA assays. The methods can facilitate detection limits into the femtomolar range, nearly four orders of magnitude lower than that of conventional ELISA assays.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit